[Form 3] Predictive Oncology Inc. Initial Statement of Beneficial Ownership
Joshua Blacher, identified as Interim CFO and an officer of Predictive Oncology Inc. (POAI), filed an initial Form 3 disclosing that he does not beneficially own any securities of the issuer. The report lists the relevant event date as 10/01/2023 and includes a signed remark that the Form 3 is being filed late due to an inadvertent administrative oversight; the filer states he is submitting the form promptly upon discovery and intends to comply with future Section 16(a) filing requirements. No non-derivative or derivative holdings are reported on this form.
Joshua Blacher, identificato come CFO ad interim e officer di Predictive Oncology Inc. (POAI), ha presentato un primo Form 3 dichiarando che non detiene in modo vantaggioso alcuna securities dell’emittente. Il rapporto riporta la data dell’evento rilevante come 10/01/2023 e include una nota firmata secondo cui il Form 3 è stato presentato in ritardo a causa di una svista amministrativa involontaria; il presentatore dichiara di inviare il modulo tempestivamente non appena ne viene a conoscenza e di voler rispettare in futuro i requisiti di deposito della Sezione 16(a). Non sono riportate partecipazioni non-derivate né derivate in questo modulo.
Joshua Blacher, identificado como CFO interino y funcionario de Predictive Oncology Inc. (POAI), presentó un Form 3 inicial indicando que no posee valor alguno de la emisora de forma beneficiosa. El informe señala la fecha del evento relevante como 01/10/2023 e incluye una observación firmada de que el Form 3 se envía con retraso debido a un olvido administrativo involuntario; el declarante afirma que envía el formulario de inmediato al descubrirlo y tiene la intención de cumplir con los futuros requisitos de presentación de la Sección 16(a). No se reportan participaciones no derivadas ni derivadas en este formulario.
Joshua Blacher는 Predictive Oncology Inc. (POAI)의 임시 CFO이자 임원으로 식별되며, 해당 발행인의 유가 증권을 실질적으로 소유하지 않음을 밝힌 초기 Form 3를 제출했습니다. 보고서는 관련 사건 날짜를 2023년 10월 1일로 기재하고, 관리상 무의식적인 누락으로 인해 Form 3이 지연 제출되었다는 서명된 주석을 포함합니다; 제출자는 발견 즉시 양식을 제출하고 향후 Section 16(a) 제출 요건을 준수할 의향이 있음을 밝힙니다. 본 양식에는 비파생 또는 파생 보유가 보고되지 않습니다.
Joshua Blacher, identifié comme directeur financier par intérim et dirigeant de Predictive Oncology Inc. (POAI), a déposé un Form 3 initial indiquant qu’il ne détient pas, en tant que bénéficiaire, de titres de l’émetteur. Le rapport indique la date de l’événement pertinent comme 01/10/2023 et comprend une note signée indiquant que le Form 3 est déposé tardivement en raison d’un oubli administratif involontaire; le déclarant affirme déposer le formulaire dès qu’il en prend connaissance et qu’il a l’intention de se conformer à l’avenir aux exigences de dépôt de la Section 16(a). Aucune détention non dérivée ni dérivée n’est indiquée dans ce formulaire.
Joshua Blacher, identifiziert als Interim-CFO und Beamter von Predictive Oncology Inc. (POAI), hat ein erstes Formular 3 eingereicht und darin angegeben, dass er keine wirtschaftlich vorteilhaft gehaltenen Wertpapiere des Emittenten besitzt. Der Bericht nennt das relevante Ereignisdatum als 01.10.2023 und enthält eine unterzeichnete Bemerkung, dass das Formular 3 aufgrund eines unbeabsichtigten administrativen Versäumnisses verspätet eingereicht wird; der Einreicher erklärt, das Formular sofort nach Feststellung einzureichen und künftig die Anforderungen der Section 16(a) zu erfüllen. Im Formular werden keine nicht-derivativen oder derivativen Bestände angegeben.
Joshua Blacher، المعرف كـCFO مؤقت وموظف في Predictive Oncology Inc. (POAI)، قدم النموذج الأول Form 3 مُعلنًا أنه لا يملك أية أوراق مالية تخص المصدر بشكل مباشر. يذكر التقرير تاريخ الحدث المعني كـ01/10/2023 ويشمل ملاحظة موقعة تفيد بأن Form 3 قدم متأخرًا بسبب سهو إداري غير مقصود؛ يذكر المُقدم أنه سيقدم النموذج على الفور عند اكتشافه وأنه يعتزم الالتزام بمتطلبات الإيداع في القسم 16(a) في المستقبل. لا توجد أي ممتلكات غير مشتقة أو مشتقة مذكورة في هذا النموذج.
- Initial disclosure made to satisfy Section 16(a) requirements despite being late
- Clear statement of no beneficial ownership, eliminating immediate insider-holding questions
- Late filing due to an administrative oversight, indicating a lapse in reporting controls
Insights
TL;DR: Officer filed an initial Form 3 reporting no holdings, but the filing was late and remedial disclosure was made.
The filing is procedural: an initial beneficial ownership statement was submitted by the Interim CFO showing zero direct or indirect holdings. From a compliance perspective, the late filing is noteworthy because Section 16(a) requires prompt reporting of such events; however, the filing includes a clear explanation attributing the delay to an administrative oversight and an assertion of intent to comply going forward. There is no reported ownership that would create immediate insider trading or disclosure obligations tied to securities transfers.
TL;DR: Governance impact is minimal: no holdings disclosed, but late filing raises internal control questions.
The substantive content shows no securities beneficially owned by the reporting officer, so there is no change to ownership structure. The admission of a late filing suggests a weakness in internal recordkeeping or reporting processes; the company and the reporting person should ensure controls are in place to prevent future lapses. Absent additional violations or repeated delays, this single remedial filing is unlikely to be material to investors.
Joshua Blacher, identificato come CFO ad interim e officer di Predictive Oncology Inc. (POAI), ha presentato un primo Form 3 dichiarando che non detiene in modo vantaggioso alcuna securities dell’emittente. Il rapporto riporta la data dell’evento rilevante come 10/01/2023 e include una nota firmata secondo cui il Form 3 è stato presentato in ritardo a causa di una svista amministrativa involontaria; il presentatore dichiara di inviare il modulo tempestivamente non appena ne viene a conoscenza e di voler rispettare in futuro i requisiti di deposito della Sezione 16(a). Non sono riportate partecipazioni non-derivate né derivate in questo modulo.
Joshua Blacher, identificado como CFO interino y funcionario de Predictive Oncology Inc. (POAI), presentó un Form 3 inicial indicando que no posee valor alguno de la emisora de forma beneficiosa. El informe señala la fecha del evento relevante como 01/10/2023 e incluye una observación firmada de que el Form 3 se envía con retraso debido a un olvido administrativo involuntario; el declarante afirma que envía el formulario de inmediato al descubrirlo y tiene la intención de cumplir con los futuros requisitos de presentación de la Sección 16(a). No se reportan participaciones no derivadas ni derivadas en este formulario.
Joshua Blacher는 Predictive Oncology Inc. (POAI)의 임시 CFO이자 임원으로 식별되며, 해당 발행인의 유가 증권을 실질적으로 소유하지 않음을 밝힌 초기 Form 3를 제출했습니다. 보고서는 관련 사건 날짜를 2023년 10월 1일로 기재하고, 관리상 무의식적인 누락으로 인해 Form 3이 지연 제출되었다는 서명된 주석을 포함합니다; 제출자는 발견 즉시 양식을 제출하고 향후 Section 16(a) 제출 요건을 준수할 의향이 있음을 밝힙니다. 본 양식에는 비파생 또는 파생 보유가 보고되지 않습니다.
Joshua Blacher, identifié comme directeur financier par intérim et dirigeant de Predictive Oncology Inc. (POAI), a déposé un Form 3 initial indiquant qu’il ne détient pas, en tant que bénéficiaire, de titres de l’émetteur. Le rapport indique la date de l’événement pertinent comme 01/10/2023 et comprend une note signée indiquant que le Form 3 est déposé tardivement en raison d’un oubli administratif involontaire; le déclarant affirme déposer le formulaire dès qu’il en prend connaissance et qu’il a l’intention de se conformer à l’avenir aux exigences de dépôt de la Section 16(a). Aucune détention non dérivée ni dérivée n’est indiquée dans ce formulaire.
Joshua Blacher, identifiziert als Interim-CFO und Beamter von Predictive Oncology Inc. (POAI), hat ein erstes Formular 3 eingereicht und darin angegeben, dass er keine wirtschaftlich vorteilhaft gehaltenen Wertpapiere des Emittenten besitzt. Der Bericht nennt das relevante Ereignisdatum als 01.10.2023 und enthält eine unterzeichnete Bemerkung, dass das Formular 3 aufgrund eines unbeabsichtigten administrativen Versäumnisses verspätet eingereicht wird; der Einreicher erklärt, das Formular sofort nach Feststellung einzureichen und künftig die Anforderungen der Section 16(a) zu erfüllen. Im Formular werden keine nicht-derivativen oder derivativen Bestände angegeben.
Joshua Blacher، المعرف كـCFO مؤقت وموظف في Predictive Oncology Inc. (POAI)، قدم النموذج الأول Form 3 مُعلنًا أنه لا يملك أية أوراق مالية تخص المصدر بشكل مباشر. يذكر التقرير تاريخ الحدث المعني كـ01/10/2023 ويشمل ملاحظة موقعة تفيد بأن Form 3 قدم متأخرًا بسبب سهو إداري غير مقصود؛ يذكر المُقدم أنه سيقدم النموذج على الفور عند اكتشافه وأنه يعتزم الالتزام بمتطلبات الإيداع في القسم 16(a) في المستقبل. لا توجد أي ممتلكات غير مشتقة أو مشتقة مذكورة في هذا النموذج.
Joshua Blacher，被确认为 Predictive Oncology Inc. (POAI) 的临时首席财务官及公司高管，提交了初始的 Form 3，披露他< b>并无对发行人拥有受益的证券。报告将相关事件日期记为 2023/10/01，并附有签名的说明，称 Form 3 因一次无意的行政疏忽而延迟提交；申报人表示在发现后将立即提交，并计划在未来遵守第16(a)条款的申报要求。该表格未报告任何非衍生或衍生持股。
FAQ
What did the Form 3 filed by Joshua Blacher for POAI disclose?
When is the event date reported on the Form 3 for POAI?
Was the Form 3 filed on time?
Does the filing report any derivative or non-derivative holdings?
What corrective action does the reporting person state?
